Luis Estevez

Senior Associate, Patient Advocacy at Avidity

Luis Estevez has a diverse work experience, starting with their current role as a Senior Associate in Patient Advocacy at Avidity Biosciences, Inc. Luis joined the company in April 2023 and is currently still employed. Prior to this, they worked as a Senior Research Associate from July 2022 to June 2023, and as a Research Associate from January 2020 to June 2022, both also at Avidity Biosciences, Inc.

Before joining Avidity Biosciences, Inc., Luis worked at the University of San Diego in various roles. Luis started in 2017 as an Athletics - Facilities and Operations Student Employee, where they initially worked as an equipment manager for the USD football program. Later, they gained experience in the operations side of USD athletic events, ensuring a positive experience for all guests. Luis held this position from March 2017 to May 2019.

During their time at the University of San Diego, Luis also worked as an Undergraduate Researcher at the University of San Diego College of Arts and Sciences from June 2017 to December 2018, and as a Pre-Undergraduate Research Experience participant from June 2014 to August 2014.

Before their university roles, Luis worked as a Store Associate at In-N-Out Burger from June 2015 to February 2017.

Overall, Luis Estevez has extensive experience in research, operations, and customer service, with a focus in the biotechnology industry.

Luis Estevez completed their Bachelor of Arts degree in Biochemistry at the University of San Diego between 2014 and 2019. In addition, they participated in a Study Abroad intersession in 2019 at Mbarara University of Science & Technology, where they focused on Water Quality and Public Health in the Developing World.

Location

San Diego, United States

Links

Previous companies


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices


Avidity

2 followers

Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.


Employees

51-200

Links